mesar 40 mg apvalkotās tabletes
menarini international operations luxembourg s.a., luxembourg - olmesartāna medoksomils - apvalkotā tablete - 40 mg
visipaque 320 mg i/ml šķīdums injekcijām
ge healthcare ae, greece - jodiksanols - Šķīdums injekcijām - 652 mg/ml
visipaque 270 mg i/ml šķīdums injekcijām
ge healthcare ae, greece - jodiksanols - Šķīdums injekcijām - 550 mg/ml
aptamil® mātes piena papildinātājs pulveris
sia ''nutricia'' 40103070928 gustava zemgala gatve 74, rīga, lv-1039, latvija - pulveris - īpašiem medicīniskiem nolūkiem paredzēta pārtika - Īpašiem medicīniskiem nolūkiem paredzēta pārtika
creatine monohydrate pulveris
bellum, sia lv40003202289 artilērijas 13 k.2-20, rīga - pulveris - cits - pārtikas produkts, kas paredzēts intensīvas muskuļu piepūles gadījumos, īpaši sportistiem
regkirona
celltrion healthcare hungary kft. - regdanvimab - covid-19 virus infection - un imūnglobulīni, - regdanvimab is indicated for the treatment of adults with coronavirus disease 2019 (covid-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.
lupkynis
otsuka pharmaceutical netherlands b.v. - voclosporin - lupus nephritis - imūnsupresanti - lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class iii, iv or v (including mixed class iii/v and iv/v) lupus nephritis (ln).
locametz
novartis europharm limited - gozetotide - radionuklīdu attēlveidošana - diagnostikas radiofarmaceitiskie preparāti - Šīs zāles ir paredzētas tikai diagnostikas vajadzībām. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.
pylclari
curium pet france - piflufolastat (18f) - prostatas audzēji - diagnostikas radiofarmaceitiskie preparāti - Šīs zāles ir paredzētas tikai diagnostikas vajadzībām. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).
iohexol icg farma 647 mg/ml šķīdums injekcijām
uab icg farma, lithuania - joheksols - Šķīdums injekcijām - 647 mg/ml